notype for rs12979860/rs8099917 showed a significant correlation with higher HCVRNA levels, the presence of mixed cryoglobulinemia and insulin resistance. Furthermore, in our cohort of 541 patients affected by CHC and treated with PEGIFN/ribavirin we retrospectively evaluated baseline HCV-RNA according to the combined genotypes of IL28B rs8099917 and rs12979860. The results are as follows ( fig. 1 ): 192 patients presented the TT/ Dear Editor, The role of interleukin (IL)-28B has been described in the treatment response and the spontaneous clearance of hepatitis C virus (HCV) infection [1] , but recently several studies have examined the effect of the IL28B genotype and the natural course of chronic hepatitis C (CHC), especially regarding the fibrosis progression and liver inflammation. In an interesting paper by Noureddin et al. [2] the IL28B rs12979860 CC genotype, already known for its higher response rate to pegylated interferon (PEGIFN) treatment, was associated with hepatic inflammation and worse clinical outcomes; also the rs8099917 GG genotype was associated with slower fibrosis progression than the TT genotype in Caucasian patients [3] . Another important contribution by Grebely et al. [4] highlighted the role of the IL28B genotype in HCV-RNA levels as an important factor that can affect the progression of fibrosis in CHC; however, the role of IL28B in influencing the baseline viral load is still poorly understood and considered in clinical studies. Patients with CC or TT genotypes present a higher baseline viral load than CT/TT or TG/GG genotypes, despite a greater chance of viral clearance or response to PEG-IFN. Regarding this finding, in our previous published study we reported that the IL28B genotypes were related both to baseline viremia and to the presence or absence of mixed cryoglobulinemia [5] . Patients with the TT/CC gePublished online: September 8, 2016
[1]
A. D’Avolio,et al.
Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment
,
2015,
Archives of Virology.
[2]
G. di Perri,et al.
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms.
,
2014,
Antiviral research.
[3]
B. Grady,et al.
Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?
,
2014,
Hepatology.
[4]
T. Liang,et al.
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis
,
2013,
Hepatology.
[5]
C. Xiang,et al.
Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.
,
2013,
Gene.
[6]
Z. Kutalik,et al.
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non‐1 HCV genotypes
,
2012,
Hepatology.